Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death

Robert P. Thomas, Buckminster J. Farrow, Sunghoon Kim, Michael J. May, Mark Hellmich, B. Mark Evers

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, selectively induces apoptosis in various cancer cells; however, certain cancers can evade TRAIL-mediated apoptosis. FLICE-like inhibitory protein (FLIP), an inhibitor of caspase-8, (also known as FLICE) is regulated by the transcription factor nuclear factor-kappaB (NF-κB) and can contribute to TRAIL resistance. The purpose of our study was to determine whether inhibition of NF-κB can enhance TRAIL-mediated pancreatic cancer cell death and decrease FLIP levels. Methods. The human pancreatic cancer cell lines MIA PaCa-2 and L3.6 were treated with TRAIL, NEMO-binding domain (NBD) peptide (a novel selective NF-κB inhibitor), or a combination of both. Cell viability and apoptosis were measured. Gel mobility shift assays were performed to assess NF-κB binding activity. Western blots were performed to assess FLIP levels after treatment with NBD or infection with an adenovirus encoding mutated IkappaBalpha. Results. The aggressive L3.6 cell line was resistant to TRAIL treatment, whereas MIA PaCa-2 cells were sensitive to TRAIL. The combination of TRAIL and NBD significantly decreased cell viability and increased apoptosis in L3.6 cells. Cellular levels of FLIP were decreased by inhibition of NF-κB (either by NBD treatment or mutant IkappaBalpha infection). Conclusions. Our findings demonstrate resistance of the aggressive L3.6 pancreatic cell line to TRAIL treatment alone; inhibition of NF-κB by NBD increased TRAIL-mediated cell death and decreased FLIP protein levels. Novel agents that selectively target the NF-κB pathway may be useful adjuvant therapies for chemoresistant pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)127-134
Number of pages8
JournalSurgery
Volume132
Issue number2
DOIs
StatePublished - Aug 2002

Fingerprint

CASP8 and FADD-Like Apoptosis Regulating Protein
Pancreatic Neoplasms
Cell Death
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
Cell Line
Cell Survival
Adenoviridae Infections
Caspase 8
Electrophoretic Mobility Shift Assay
Neoplasms
Transcription Factors
Western Blotting
Gels
Infection
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. / Thomas, Robert P.; Farrow, Buckminster J.; Kim, Sunghoon; May, Michael J.; Hellmich, Mark; Evers, B. Mark.

In: Surgery, Vol. 132, No. 2, 08.2002, p. 127-134.

Research output: Contribution to journalArticle

Thomas, Robert P. ; Farrow, Buckminster J. ; Kim, Sunghoon ; May, Michael J. ; Hellmich, Mark ; Evers, B. Mark. / Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. In: Surgery. 2002 ; Vol. 132, No. 2. pp. 127-134.
@article{98c1d81bcdcf48a58a424971f6fb8cb4,
title = "Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death",
abstract = "Background. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, selectively induces apoptosis in various cancer cells; however, certain cancers can evade TRAIL-mediated apoptosis. FLICE-like inhibitory protein (FLIP), an inhibitor of caspase-8, (also known as FLICE) is regulated by the transcription factor nuclear factor-kappaB (NF-κB) and can contribute to TRAIL resistance. The purpose of our study was to determine whether inhibition of NF-κB can enhance TRAIL-mediated pancreatic cancer cell death and decrease FLIP levels. Methods. The human pancreatic cancer cell lines MIA PaCa-2 and L3.6 were treated with TRAIL, NEMO-binding domain (NBD) peptide (a novel selective NF-κB inhibitor), or a combination of both. Cell viability and apoptosis were measured. Gel mobility shift assays were performed to assess NF-κB binding activity. Western blots were performed to assess FLIP levels after treatment with NBD or infection with an adenovirus encoding mutated IkappaBalpha. Results. The aggressive L3.6 cell line was resistant to TRAIL treatment, whereas MIA PaCa-2 cells were sensitive to TRAIL. The combination of TRAIL and NBD significantly decreased cell viability and increased apoptosis in L3.6 cells. Cellular levels of FLIP were decreased by inhibition of NF-κB (either by NBD treatment or mutant IkappaBalpha infection). Conclusions. Our findings demonstrate resistance of the aggressive L3.6 pancreatic cell line to TRAIL treatment alone; inhibition of NF-κB by NBD increased TRAIL-mediated cell death and decreased FLIP protein levels. Novel agents that selectively target the NF-κB pathway may be useful adjuvant therapies for chemoresistant pancreatic cancers.",
author = "Thomas, {Robert P.} and Farrow, {Buckminster J.} and Sunghoon Kim and May, {Michael J.} and Mark Hellmich and Evers, {B. Mark}",
year = "2002",
month = "8",
doi = "10.1067/msy.2002.124930",
language = "English (US)",
volume = "132",
pages = "127--134",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Selective targeting of the nuclear factor-κB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death

AU - Thomas, Robert P.

AU - Farrow, Buckminster J.

AU - Kim, Sunghoon

AU - May, Michael J.

AU - Hellmich, Mark

AU - Evers, B. Mark

PY - 2002/8

Y1 - 2002/8

N2 - Background. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, selectively induces apoptosis in various cancer cells; however, certain cancers can evade TRAIL-mediated apoptosis. FLICE-like inhibitory protein (FLIP), an inhibitor of caspase-8, (also known as FLICE) is regulated by the transcription factor nuclear factor-kappaB (NF-κB) and can contribute to TRAIL resistance. The purpose of our study was to determine whether inhibition of NF-κB can enhance TRAIL-mediated pancreatic cancer cell death and decrease FLIP levels. Methods. The human pancreatic cancer cell lines MIA PaCa-2 and L3.6 were treated with TRAIL, NEMO-binding domain (NBD) peptide (a novel selective NF-κB inhibitor), or a combination of both. Cell viability and apoptosis were measured. Gel mobility shift assays were performed to assess NF-κB binding activity. Western blots were performed to assess FLIP levels after treatment with NBD or infection with an adenovirus encoding mutated IkappaBalpha. Results. The aggressive L3.6 cell line was resistant to TRAIL treatment, whereas MIA PaCa-2 cells were sensitive to TRAIL. The combination of TRAIL and NBD significantly decreased cell viability and increased apoptosis in L3.6 cells. Cellular levels of FLIP were decreased by inhibition of NF-κB (either by NBD treatment or mutant IkappaBalpha infection). Conclusions. Our findings demonstrate resistance of the aggressive L3.6 pancreatic cell line to TRAIL treatment alone; inhibition of NF-κB by NBD increased TRAIL-mediated cell death and decreased FLIP protein levels. Novel agents that selectively target the NF-κB pathway may be useful adjuvant therapies for chemoresistant pancreatic cancers.

AB - Background. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, selectively induces apoptosis in various cancer cells; however, certain cancers can evade TRAIL-mediated apoptosis. FLICE-like inhibitory protein (FLIP), an inhibitor of caspase-8, (also known as FLICE) is regulated by the transcription factor nuclear factor-kappaB (NF-κB) and can contribute to TRAIL resistance. The purpose of our study was to determine whether inhibition of NF-κB can enhance TRAIL-mediated pancreatic cancer cell death and decrease FLIP levels. Methods. The human pancreatic cancer cell lines MIA PaCa-2 and L3.6 were treated with TRAIL, NEMO-binding domain (NBD) peptide (a novel selective NF-κB inhibitor), or a combination of both. Cell viability and apoptosis were measured. Gel mobility shift assays were performed to assess NF-κB binding activity. Western blots were performed to assess FLIP levels after treatment with NBD or infection with an adenovirus encoding mutated IkappaBalpha. Results. The aggressive L3.6 cell line was resistant to TRAIL treatment, whereas MIA PaCa-2 cells were sensitive to TRAIL. The combination of TRAIL and NBD significantly decreased cell viability and increased apoptosis in L3.6 cells. Cellular levels of FLIP were decreased by inhibition of NF-κB (either by NBD treatment or mutant IkappaBalpha infection). Conclusions. Our findings demonstrate resistance of the aggressive L3.6 pancreatic cell line to TRAIL treatment alone; inhibition of NF-κB by NBD increased TRAIL-mediated cell death and decreased FLIP protein levels. Novel agents that selectively target the NF-κB pathway may be useful adjuvant therapies for chemoresistant pancreatic cancers.

UR - http://www.scopus.com/inward/record.url?scp=0036672868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036672868&partnerID=8YFLogxK

U2 - 10.1067/msy.2002.124930

DO - 10.1067/msy.2002.124930

M3 - Article

VL - 132

SP - 127

EP - 134

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -